Background
Patients and methods
Patients
patient | normal range | #1 | #2 | #3 | #4 | #5 | #6 |
---|---|---|---|---|---|---|---|
TNSALP in leukocytes | 2–18 nmol/min/mg protein | 0.1 | 0 | 0.11 | 0.1 | 0.1 | 0.5 |
PEA in serum/plasma | 0–60 μmol/l | 25 | Nd | 98 | 6 | 7 | 97 |
PEA/Cr in urine | 9–25 mmol/mol Cr | 252 | 148 | 250 | 157 | 117 | 155 |
PLP in plasma | 5–30 ng/ml | 1039 | 408 | 185 | 324 | 446 | 165 |
Age
| years | 2 | 2,5 | 3 | 7,42 | 9 | 13 |
Bone metabolic profile
Prostaglandin profile in the urine during NSAID treatment
Cell culture
Isolation of RNA and synthesis of first strand complementary DNA
Quantification of cDNA in samples
Polymerase chain reaction (PCR)
Enzyme linked immunosorbant assay (ELISA)
Statistical analysis
Results
Bone metabolism in patients
Evaluation of "on demand" NSAID treatment in all patients
Long-term prospective evaluation of NSAID treatment
1. Cycle | 2. Cycle | 3. Cycle | 4. Cycle | after 8 wks | |||||
---|---|---|---|---|---|---|---|---|---|
time | before | after | before | after | before | after | before | after | pause |
overall well being, physician's global rating | 6 | 9 | 6 | 9 | 5 | 9 | 7 | 8 | 4 |
Gower's sign | 4 | 3 | 5 | 4 | 5 | 3 | 6 | 5 | 6 |
overall well being, parents' global rating | 5 | 10 | 5 | 8 | 5 | 9 | 7 | 8 | 5 |
physical activity | 2,2 | 9,6 | 3,5 | 7 | 1,2 | 7,5 | 1,2 | 2,9 | 2 |
fatigue after physical activity | 0,5 | 9,3 | 1,5 | 5 | 2,6 | 5,4 | 1,5 | 5,3 | 1,5 |
Gower's sign | 2,3 | 6,4 | 5 | 6,4 | 0,8 | 2,5 | 1,2 | 2,9 | 1,3 |
patient wants to be carried | 1,2 | 9,3 | 3,5 | 5,5 | 2,9 | 7,6 | 2,5 | 7,6 | 2,8 |
pain in rest | 3 | 7 | 1,8 | 7 | 3,25 | 9,6 | 1,6 | 9,5 | 1,7 |
pain after physical activity | 1,7 | 7 | 3,3 | 5 | 1,6 | 7,3 | 1,9 | 6,1 | 1,5 |